KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Shares Outstanding (Diluted Average) (2019 - 2025)

Rigel Pharmaceuticals (RIGL) has 10 years of Shares Outstanding (Diluted Average) data on record, last reported at $18.8 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 6.52% year-over-year to $18.8 million; the TTM value through Dec 2025 reached $18.8 million, up 6.52%, while the annual FY2025 figure was $18.8 million, 6.52% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $18.8 million in Q4 2025 per RIGL's latest filing, up from $18.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $176.5 million in Q3 2021 and bottomed at $17.0 million in Q4 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $79.8 million, with a median of $18.3 million recorded in 2025.
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 90.0% in 2022, then rose 6.52% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $170.5 million in 2021, then tumbled by 90.0% to $17.0 million in 2022, then grew by 2.06% to $17.4 million in 2023, then rose by 1.64% to $17.7 million in 2024, then rose by 6.52% to $18.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $18.8 million in Q4 2025, $18.4 million in Q3 2025, and $18.2 million in Q2 2025.